• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Akumin Announces Third Quarter 2022 Results

    11/9/22 4:30:00 PM ET
    $AKU
    Medical Specialities
    Health Care
    Get the next $AKU alert in real time by email

    PLANTATION, Fla., Nov. 9, 2022 /PRNewswire/ - Akumin Inc. (NASDAQ:AKU) (TSX:AKU) ("Akumin" or the "Company"), a national partner of choice for U.S. hospitals, health systems and physician groups with comprehensive solutions addressing outsourced radiology and oncology service-line needs, announced today its financial results for the quarter ended September 30, 2022.

    Third Quarter 2022 Highlights

    • Akumin's radiology business delivered third quarter same-store volume performance on a consolidated, pro forma basis assuming the Company's acquisition of Alliance HealthCare Services was completed as of January 1, 2021:
      • +0.2% for MRI
      • +7.8% for PET/CT
      • (2.5%) for Total Radiology Procedures
      • (0.2%) for Oncology Patient Starts
    • The Company reported revenue totaling $186.6 million during the third quarter, a 72.5% increase over the third quarter of last year, which is significantly attributable to the Company's acquisition of Alliance HealthCare Services on September 1, 2021. Revenue was lower than expected, largely due to disruptions in our Florida operations caused by Hurricane Ian and ongoing labor constraints, particularly among clinical personnel. The Company is taking steps to address the labor issues going forward.
    • Basic and diluted loss per share were $0.60 during the third quarter of 2022. This compares with a basic and diluted loss per share of $0.02 for the third quarter of 2021. The Company's net loss was $49.7 million compared to a gain of $1.2 million in the third quarter of last year. This quarter's net loss included a goodwill impairment charge of $20.0 million related to the Oncology division. The Oncology business is experiencing delays in implementing new partnerships, in part as a result of supply-chain issues. Our Oncology division is also in the process of being repositioned under new leadership and strategic direction.
    • Excluding $7.6 million from the gain on sale of certain accounts receivable, Akumin generated $36.5 million of Adjusted EBITDA (as defined below) for the third quarter of 2022, a 103.3% increase over the third quarter of last year. The Adjusted EBITDA margin profile during the third quarter of 2022 remained stable at 19.6% versus 19.9% in the second quarter of 2022.

    Commenting on the third quarter results, Riadh Zine, Chairman and Chief Executive Officer of the Company, said, "we managed to maintain our margin profile during this quarter despite the challenges we faced, including the hurricane disruption and ongoing labor constraints.  We continue to expect the fourth quarter of 2022 to reflect the full run-rate of approximately $23 million of cost synergies achieved from the completion of our first phase of transformation efforts which focused on organizational changes. We believe both the second and third phases of our transformation efforts, which are focused on network consolidation, asset optimization, and purchasing power are expected to result in more than $25 million in additional run-rate synergies during 2023."

    "Our Oncology division has undergone a comprehensive assessment under new leadership and is being repositioned to capitalize on emerging market dynamics.  We are excited about the growth opportunities in oncology given the need for hospital partners to upgrade their aging fleet of radiation therapy equipment and technology.  Our new strategic direction leverages our competitive advantages, including the core patents we own in the delivery of mobile oncology which is crucial to maintaining radiation therapy services while technological upgrades are underway" Zine continued.

    Full-Year 2022 Financial Outlook

    Commenting on the full-year ending December 31, 2022 financial outlook, Zine said, "We have revised our 2022 financial guidance given the challenges experienced during this quarter and the reduction in  capital expenditures to ensure optimal and most efficient deployment of equipment, better aligned with our strategic priorities. We now expect that the financial results of the Company for 2022 will be as follows:



    Akumin Full-Year 2022 Guidance (3)

    Revenue

    $740-750mm

    Adjusted EBITDA (1)

    $140-150mm

    Capex (2)

    $50mm

    (1) See "Non-GAAP Measures" below. Although the Company provides guidance for Adjusted EBITDA, it is not able to provide guidance for net income, the most directly comparable GAAP measure. Certain elements of the composition of net income, including stock compensation expense, are not predictable, making it impractical for the Company to provide guidance on net income or to reconcile its Adjusted EBITDA guidance to net income without unreasonable efforts. For the same reason, the Company is unable to address the probable significance of the unavailable information.

    (2) Including $26mm of growth Capex.

    (3) See "Forward-Looking Information" below.



    "Notwithstanding the challenging operating environment in the quarter, the Akumin team performed well and achieved several important milestones including the change of jurisdiction of incorporation from the Province of Ontario, Canada to the State of Delaware, USA, which was completed at quarter end.  We also increased the depth of our management team by adding several accomplished and experienced members to our senior ranks. We continue to be excited about the opportunities ahead for Akumin and have never been in a better position to capitalize on them" Zine concluded.

    Unless otherwise indicated, all amounts are expressed in U.S. dollars.  Certain financial measures, including those expressed on an adjusted, are non-GAAP measures.  See "Non-GAAP Measures" and "Reconciliation of Non-GAAP Measures" of this press release for further details.

    Investor Presentation

    Akumin would like to invite interested parties to an investor presentation to be held on Thursday, November 10, 2022 from 8:30 a.m. to 9:30 a.m. Eastern Time where management will discuss third quarter results.

    Conference call details:

    Date:                                          8:30a.m. Eastern Time, Thursday, November 10, 2022

    Click to join by phone:               https://akum.in/Q3-2022-Results-Audio Access via webcast:                  https://akum.in/Q3-2022-Results-Webcast

    A related presentation will be available from Akumin's website (www.akumin.com) and at https://akumin.com/investor-relations/events-presentations/.  Participants are asked to connect at least 10 minutes prior to the beginning of the call to ensure participation.  The webcast archive will be available for 90 days.  A replay of the presentation will also be available by calling 1-888-203-1112, or 647-436-0148 for international callers, using passcode 4397612.

    About Akumin

    Akumin is a national partner of choice for U.S. hospitals, health systems and physician groups with comprehensive solutions addressing outsourced radiology and oncology service-line needs. Akumin provides (1) fixed-site outpatient diagnostic imaging services through a network of owned and/or operated imaging locations; and (2) outpatient radiology and oncology services and solutions to approximately 1,000 hospitals and health systems across 48 states. By combining clinical and operational expertise with the latest advances in technology and information systems, Akumin facilitates diagnosis and treatment for patients and their providers. Akumin's imaging procedures include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET and PET/CT), ultrasound, diagnostic radiology (X-ray), mammography, and other related procedures; our cancer care services include a full suite of radiation therapy and related offerings. For more information, visit www.akumin.com.

    Non-GAAP Measures

    This press release refers to certain non-GAAP measures. These non-GAAP measures are not recognized measures under United States generally accepted accounting principles ("GAAP") and do not have a standardized meaning prescribed by GAAP.  The non-GAAP measures used by us are susceptible to varying methods of calculation and may not be comparable to other similarly titled measures of other companies. Rather, these non-GAAP measures are provided as additional information to complement those GAAP measures by providing further understanding of our results of operations from management's perspective. Accordingly, these non-GAAP measures should not be considered in isolation nor as a substitute for analysis of our financial information reported under GAAP. We use non-GAAP financial measures, including "EBITDA", "Adjusted EBITDA" and "Adjusted EBITDA Margin" (each as defined below). These non-GAAP measures are used to provide investors with supplemental measures of our operating performance and thus highlight trends in our core business that may not otherwise be apparent when relying solely on GAAP measures. We believe the use of these non-GAAP measures, along with GAAP financial measures, enhances the reader's understanding of our operating results and is useful to us and to investors in comparing performance with competitors, estimating enterprise value, and making investment decisions.  We also believe that securities analysts, investors, and other interested parties frequently use non-GAAP measures in the evaluation of issuers. Our management uses non-GAAP measures to facilitate operating performance comparisons from period to period, to prepare annual operating budgets and forecasts and to determine components of management compensation. Reconciliations of non-GAAP measures used to the most comparable GAAP measures are included in this release in the tables which follow.

    We define such non-GAAP measures as follows:

    "EBITDA" means net income (loss) before interest expense, income tax expense (benefit), and depreciation and amortization.

    "Adjusted EBITDA" means EBITDA, as further adjusted for impairment charges, restructuring charges, severance and related costs, settlements and related costs (recoveries), stock-based compensation, gain on sale of accounts receivable, losses (gains) on disposal of property and equipment, acquisition-related costs, financial instrument revaluation adjustments, gain on conversion of debt to equity investment, deferred rent expense, other losses (gains), and one-time adjustments.

    "Adjusted EBITDA Margin" means Adjusted EBITDA divided by the total revenue in the period.

    Forward-Looking Information

    Certain information in this press release constitutes forward-looking information or forward-looking statements.  In some cases, but not necessarily in all cases, such statements or information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information.  Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events.

    Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Akumin as of the date of this press release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on March 16, 2022, as amended by Amendment No. 1 to the Annual Report on Form 10-K, filed with the SEC on April 12, 2022 and the "Risk Factors" section of our Quarterly Report on Form 10-Q for the period ended September 30, 2022, filed with the SEC on November 9, 2022, all of which are available at www.sec.gov. These factors are not intended to represent a complete list of the factors that could affect Akumin; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this press release are made as of the date of this press release, and Akumin expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

    <Financial tables follow.>

    Selected Consolidated Financial Information

    (in thousands)

    Three Months ended

    September 30, 2022

    Three Months ended

    September 30, 2021

    $ Change

    % Change

    Revenue

    $186,605

    $108,177

    $78,428

    73 %











    Employee compensation

    67,278

    41,247

    26,031

    63 %

    Third-party services and professional fees

    30,233

    15,154

    15,079

    100 %

    Rent and utilities

    12,894

    9,507

    3,387

    36 %

    Reading fees

    11,379

    10,797

    582

    5 %

    Administrative expenses

    12,473

    7,156

    5,317

    74 %

    Medical supplies and other expenses

    16,417

    7,103

    9,314

    131 %

    Depreciation and amortization

    25,079

    11,286

    13,793

    122 %

    Impairment charges

    20,369

    -

    20,369

    nmf

    Restructuring charges

    4,042

    479

    3,563

    744 %

    Severances and related costs

    2,485

    53

    2,432

    4,589 %

    Settlements, recoveries and related costs

    (576)

    (52)

    (524)

    1,008 %

    Stock-based compensation

    556

    785

    (229)

    (29 %)

    Other operating expense, net

    (7,574)

    (68)

    (7,506)

    11,038 %

    Interest expense

    29,679

    16,932

    12,747

    75 %

    Acquisition-related costs

    99

    8,784

    (8,685)

    (99 %)

    Other non-operating income, net

    (521)

    (96)

    (425)

    443 %

    Loss before income taxes

    $(37,707)

    $(20,890)

    $(16,817)

    81 %

    Income tax expense (benefit)

    12,038

    (22,070)

    34,108

    (155 %)

    Net income (loss)

    (49,745)

    1,180

    (50,925)

    (4,316 %)

    Less: Net income attributable to noncontrolling interests

    4,126

    2,517

    1,609

    64 %

    Net loss attributable to common stockholders

    $(53,871)

    $(1,337)

    $(52,534)

    3,929 %

     

    (in thousands)

    Nine Months ended

    September 30, 2022

    Nine Months ended

    September 30, 2021

    $ Change

    % Change

    Revenue

    $564,996

    $241,636

    $323,360

    134 %











    Employee compensation

    214,426

    88,156

    126,270

    143 %

    Third-party services and professional fees

    89,271

    29,771

    59,500

    200 %

    Rent and utilities

    38,114

    24,853

    13,261

    53 %

    Reading fees

    34,665

    31,642

    3,023

    10 %

    Administrative expenses

    35,621

    16,341

    19,280

    118 %

    Medical supplies and other expenses

    48,312

    13,111

    35,201

    268 %

    Depreciation and amortization

    75,010

    20,359

    54,651

    268 %

    Impairment charges

    20,702

    -

    20,702

    nmf

    Restructuring charges

    11,366

    479

    10,887

    2,273 %

    Severances and related costs

    10,282

    53

    10,229

    19,300 %

    Settlements, recoveries and related costs

    101

    (394)

    495

    (126 %)

    Stock-based compensation

    2,375

    1,997

    378

    19 %

    Other operating expense, net

    (7,328)

    278

    (7,606)

    (2,736 %)

    Interest expense

    87,650

    34,221

    53,429

    156 %

    Acquisition-related costs

    567

    14,412

    (13,845)

    (96 %)

    Other non-operating income, net

    (3,000)

    (3,462)

    462

    (13 %)

    Loss before income taxes

    $(93,138)

    $(30,181)

    $(62,957)

    209 %

    Income tax expense (benefit)

    9,118

    (21,999)

    31,117

    (141 %)

    Net loss

    (102,256)

    (8,182)

    (94,074)

    1,150 %

    Less: Net income attributable to noncontrolling interests

    12,895

    3,388

    9,507

    281 %

    Net loss attributable to common stockholders

    $(115,151)

    $(11,570)

    $(103,581)

    895 %



    Reconciliation of Non-GAAP Measures

    (in thousands)

    Three Months

    ended September

    30, 2022

    Three Months

    ended September

    30, 2021

    Nine Months

    ended September

    30, 2022

    Nine Months

    ended September

    30, 2021

    Net income (loss)

    $(49,745)

    $1,180

    $(102,256)

    $(8,182)

    Interest expense

    29,679

    16,932

    87,650

    34,221

    Income tax expense (benefit)

    12,038

    (22,070)

    9,118

    (21,999)

    Depreciation and amortization

    25,079

    11,286

    75,010

    20,359

    EBITDA

    $17,051

    $7,328

    $69,522

    $24,399

    Adjustments:









    Impairment Charges

    20,369

    -

    20,702

    -

    Restructuring charges

    4,042

    479

    11,366

    479

    Severance and related costs

    2,485

    53

    10,282

    53

    Settlements, recoveries and related costs

    (576)

    (52)

    101

    (394)

    Stock-based compensation

    556

    785

    2,375

    1,997

    Gain on sale of accounts receivable

    (7,603)

    -

    (7,603)

    -

    Loss (gain) on disposal of property and equipment, net

    26

    (25)

    398

    321

    Acquisition-related costs

    99

    8,784

    567

    14,412

    Fair value adjustment on derivative

    (271)

    (50)

    (1,110)

    (50)

    Gain on conversion of debt to equity investment

    -

    -

    -

    (3,360)

    Deferred rent expense(1)

    325

    621

    904

    1,525

    Other, net

    18

    45

    (783)

    (1)

    Adjusted EBITDA

    $36,521

    $17,968

    $106,721

    $39,381

    Revenue

    $186,605

    $108,177

    $564,996

    $241,636

    Adjusted EBITDA Margin

    20 %

    17 %

    19 %

    16 %

     (1)   Deferred rent expense is defined as operating lease cost less operating cash flows from operating leases and adjusted for any prepayments or related items.

     

    Cision View original content:https://www.prnewswire.com/news-releases/akumin-announces-third-quarter-2022-results-301673554.html

    SOURCE Akumin Inc.

    Get the next $AKU alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AKU

    DatePrice TargetRatingAnalyst
    11/14/2022$3.50 → $3.00Buy → Speculative Buy
    Canaccord Genuity
    More analyst ratings

    $AKU
    SEC Filings

    See more
    • SEC Form EFFECT filed by Akumin Inc.

      EFFECT - AKUMIN INC. (0001776197) (Filer)

      2/13/24 12:15:09 AM ET
      $AKU
      Medical Specialities
      Health Care
    • SEC Form 15-12G filed by Akumin Inc.

      15-12G - AKUMIN INC. (0001776197) (Filer)

      2/7/24 6:11:57 AM ET
      $AKU
      Medical Specialities
      Health Care
    • SEC Form S-8 POS filed by Akumin Inc.

      S-8 POS - AKUMIN INC. (0001776197) (Filer)

      2/7/24 6:09:57 AM ET
      $AKU
      Medical Specialities
      Health Care

    $AKU
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Akumin Announces Changes to Leadership Team

      Krishna Kumar, Current President & Chief Operating Officer, Appointed Chief Executive Officer Chandra Westergaard Named General Counsel PLANTATION, Fla., Feb. 8, 2024 /CNW/ - Akumin Inc. ("Akumin" or the "Company") announced today that Krishna Kumar, who has served as President and Chief Operating Officer at the Company, has been appointed Chief Executive Officer, effective immediately. He succeeds Riadh Zine, Akumin's Founder, who is stepping down as Chairman and Chief Executive Officer. Akumin also announced that Chandra Westergaard has been named General Counsel and will oversee the Company's legal and compliance functions. "On behalf of Akumin, I would like to thank Riadh for his dedica

      2/8/24 5:00:00 PM ET
      $AKU
      Medical Specialities
      Health Care
    • Akumin Inc. Completes Deleveraging Transaction, Becomes a Private Company Wholly-Owned by Stonepeak

      Akumin well-positioned to continue providing top-quality radiology and oncology services to patients, health systems, hospitals, and physician groups across the U.S. PLANTATION, Fla., Feb. 6, 2024 /CNW/ - Akumin Inc. ("Akumin" or the "Company") today announced that it has completed its deleveraging transaction, becoming a private company wholly-owned by Stonepeak, a leading alternative investment firm specializing in infrastructure and real assets. The deleveraging and recapitalization transaction was implemented through a voluntary, court-supervised financial restructuring process, which is now complete. "We are pleased to have concluded this process and are excited to enter our next chapt

      2/6/24 6:26:00 PM ET
      $AKU
      Medical Specialities
      Health Care
    • Akumin Inc. Provides Update on its Restructuring Transaction

      /NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES/  PLANTATION, Fla., Jan. 31, 2024 /CNW/ - Akumin Inc. (together with its subsidiaries, "we", "us", "our," "Akumin" or the "Company") (TSX:AKU) (OTC Pink Open Market: AKUMQ) announced today that its previously announced restructuring transaction involving Stonepeak as well as its bondholders, lenders, shareholders and other stakeholders under a prepackaged chapter 11 plan of reorganization (the "Prepackaged Plan") is expected to become effective on or around February 6, 2024 (the "Effective Date"), subject to satisfaction of all of the remaining conditions to the closing of the restructuring transaction. On

      1/31/24 10:26:00 PM ET
      $AKU
      Medical Specialities
      Health Care

    $AKU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Foursixthree Capital Lp claimed ownership of 10,556,851 shares (SEC Form 3)

      3 - AKUMIN INC. (0001776197) (Issuer)

      2/5/24 4:50:02 PM ET
      $AKU
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Bienias Ronald J.

      3 - AKUMIN INC. (0001776197) (Issuer)

      10/26/23 10:40:46 AM ET
      $AKU
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Kumar Krishna

      4 - AKUMIN INC. (0001776197) (Issuer)

      7/18/23 1:31:57 PM ET
      $AKU
      Medical Specialities
      Health Care

    $AKU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Akumin downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded Akumin from Buy to Speculative Buy and set a new price target of $3.00 from $3.50 previously

      11/14/22 8:59:34 AM ET
      $AKU
      Medical Specialities
      Health Care

    $AKU
    Financials

    Live finance-specific insights

    See more
    • Akumin Inc. Provides Update on its Restructuring Transaction

      /NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES/  PLANTATION, Fla., Jan. 31, 2024 /CNW/ - Akumin Inc. (together with its subsidiaries, "we", "us", "our," "Akumin" or the "Company") (TSX:AKU) (OTC Pink Open Market: AKUMQ) announced today that its previously announced restructuring transaction involving Stonepeak as well as its bondholders, lenders, shareholders and other stakeholders under a prepackaged chapter 11 plan of reorganization (the "Prepackaged Plan") is expected to become effective on or around February 6, 2024 (the "Effective Date"), subject to satisfaction of all of the remaining conditions to the closing of the restructuring transaction. On

      1/31/24 10:26:00 PM ET
      $AKU
      Medical Specialities
      Health Care
    • Akumin Announces Second Quarter 2023 Results, Revised FY23 Financial Outlook and Establishment of Special Committee

      PLANTATION, Fla., Aug. 9, 2023 /PRNewswire/ - Akumin Inc. (NASDAQ:AKU) (TSX:AKU) ("Akumin" or the "Company"), a national partner of choice for U.S. hospitals, health systems and physician groups, with comprehensive solutions addressing outsourced radiology and oncology service-line needs, announced today its financial results for the quarter ended June 30, 2023. Second Quarter 2023 Highlights Akumin delivered second quarter same-store volume performance on a consolidated basis as follows:+3.1% for MRI+16.5% for PET/CT+3.4% for Oncology Patient StartsThe Company reported revenue totaling $184.8 million for the second quarter, a $7.3 million or 4% decrease over the second quarter of last year.

      8/9/23 5:23:00 PM ET
      $AKU
      Medical Specialities
      Health Care
    • Akumin to Host Second Quarter 2023 Financial Results Call on August 10, 2023

      PLANTATION, Fla., Aug. 8, 2023 /PRNewswire/ - Akumin Inc. (TSX:AKU) ("Akumin" or the "Company") will host a conference call at 8:30 a.m. Eastern Time, Thursday, August 10, 2023, to discuss its second quarter 2023 financial results.  The financial results are expected to be available on Wednesday, August 9, 2023. To access the conference call, participants may join by using an appropriate dial-in number available through https://akum.in/Q2-2023-Results-Dial-In-Numbers or via webcast at https://akum.in/Q2-2023-Results-Webcast. A related presentation will be available from Akumin's website (www.akumin.com). Participants are asked to connect at least 10 minutes prior to the beginning of the call

      8/8/23 5:23:00 PM ET
      $AKU
      Medical Specialities
      Health Care

    $AKU
    Leadership Updates

    Live Leadership Updates

    See more
    • AKUMIN ANNOUNCES LEADERSHIP TRANSITION

      PLANTATION, Fla., Dec. 29, 2023 /CNW/ - Akumin Inc. (together with its subsidiaries, "we", "us", "our," "Akumin" or the "Company") (TSX:AKU) (OTC Pink Open Market: AKUMQ) announced today that its Board of Directors has appointed Ronald J. Bienias, Akumin's Chief Restructuring Officer and Partner and Managing Director of AlixPartners, LLP, as Interim Chief Financial Officer, effective today. He will also maintain his current role as Chief Restructuring Officer. Ronald's appointment follows the resignation of David Kretschmer, as Akumin's Chief Financial Officer effective today. Ronald has more than 20 years of experience serving in interim leadership roles or as an advisor at both large and

      12/29/23 7:52:00 PM ET
      $AKU
      Medical Specialities
      Health Care
    • Akumin Announces Change of Auditor

      PLANTATION, Fla., Aug. 9, 2023 /PRNewswire/ - Akumin Inc. ("Akumin" or the "Company") (NASDAQ:AKU) (TSX:AKU) announced today that it has changed its auditor from Ernst & Young LLP ("EY") to Deloitte & Touche LLP ("Deloitte"). Effective as of August 9, 2023, the audit committee (the "Audit Committee") of the board of directors (the "Board") of the Company dismissed EY as the Company's independent registered public accounting firm. EY audited the Company's financial statements for each of the past two fiscal years ended December 31, 2022 and 2021, and EY's reports did not contain any adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or

      8/9/23 5:31:00 PM ET
      $AKU
      Medical Specialities
      Health Care
    • Akumin appoints President and Chief Operating Officer

      PLANTATION, Fla., June 12, 2023 /CNW/ - Akumin Inc. ("Akumin" or the "Company") (NASDAQ:AKU) (TSX:AKU) today announced the appointment of Krishna Kumar as President and Chief Operating Officer of the Company, effective as of June 16, 2023. Krishna has valuable experience and exceptional insight into the radiology space, having served as Senior Vice President & Business Leader - Precision Diagnosis at Philips North America, where he built a top performing team and business, over the last four years. Prior to this role, he led global businesses in Pathology, Oncology and Neuro at Philips based in Amsterdam, Netherlands from 2015-2019 and prior thereto was the CEO of Philips India. Before joini

      6/12/23 6:59:57 AM ET
      $AKU
      Medical Specialities
      Health Care

    $AKU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Akumin Inc. (Amendment)

      SC 13G/A - AKUMIN INC. (0001776197) (Subject)

      2/12/24 4:37:41 PM ET
      $AKU
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Akumin Inc.

      SC 13G - AKUMIN INC. (0001776197) (Subject)

      2/12/24 4:31:27 PM ET
      $AKU
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Akumin Inc. (Amendment)

      SC 13G/A - AKUMIN INC. (0001776197) (Subject)

      2/7/24 10:43:55 AM ET
      $AKU
      Medical Specialities
      Health Care